Drug news
Zykadia agreement will aid ALK positive (anaplastic lymphoma kinase positive) Non Small Cell Lung Cancer patients
The National Institute for Health and Care Excellence (NICE) in draft guidance has recommended Zykadia (ceritinib) from Novartis as an option for treatment of adults with untreated ALK positive (anaplastic lymphoma kinase positive) Non Small Cell Lung Cancer. This recommendation followed an agreement of a confidential discount. Zykadia is already recommended for previously treated patients.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.